Welcome, Guest. Please login or register.
May 26, 2019, 11:56:05 pm

Login with username, password and session length


Members
  • Total Members: 6097
  • Latest: Sage
Stats
  • Total Posts: 54085
  • Total Topics: 4554
  • Online Today: 80
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 70
Total: 70

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Hep C Treatment Type Not Tied to Liver Cancer Recurrence Risk  (Read 1318 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 599
    • Hep Mag
Hep C Treatment Type Not Tied to Liver Cancer Recurrence Risk
« on: December 12, 2018, 10:37:13 am »
A recent study showed no difference in the rate of hepatocellular carcinoma (HCC, the most common form of liver cancer) recurrence based on the type of hepatitis C virus (HCV) treatment received, Healio reports.

Some controversy persists among members of the hep C research community as to whether those who have had liver cancer and receive HCV treatment are in fact at lower risk of liver cancer if they receive the older treatment of interferon compared with taking the newer direct-acting antivirals (DAA). Multiple recent studies have refuted this presumption.

Read more...
https://www.hepmag.com/article/hep-c-treatment-type-tied-liver-cancer-recurrence-risk

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.